ReviewPituitary2015
Update on prognostic factors in acromegaly: Is a risk score possible?
Review in Pituitary, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Clinical Features and Key Prognostic Indicators of Growth Hormone-Secreting Pituitary Adenomas: A Retrospective Study of 344 Cases.Current oncology (Toronto, Ont.) · 2026Article
- The Journey of Acromegaly Towards Treatment: A Single-Center Study.Journal of personalized medicine · 2026Article
- Is Knosp enough? A novel classification for Acromegaly: a retrospective analysis of cure rates and outcome predictors in a large tertiary centre.Acta neurochirurgica · 2025Article
- Predictors of biochemical and structural response to medical therapy in patients with active acromegaly following surgery: a real-world perspective.BMC endocrine disorders · 2025Article
- Diagnostic, therapeutic, and prognostic characteristics of patients with acromegaly according to tumor size at diagnosis.Pituitary · 2024Observational
- Diagnosis and Management of Aggressive/Refractory Growth Hormone-Secreting Pituitary Neuroendocrine Tumors.International journal of endocrinology · 2024Review
- Article
- Giant growth hormone-secreting pituitary adenomas from the endocrinologist's perspective.Endocrine · 2023Article
- Article
- Predictors of postoperative biochemical remission in acromegaly.Journal of neuro-oncology · 2021Article
- Precision Therapy in Acromegaly Caused by Pituitary Tumors: How Close Is It to Reality?Endocrinology and metabolism (Seoul, Korea) · 2020Review
- Potential markers of disease behavior in acromegaly and gigantism.Expert review of endocrinology & metabolism · 2020Review
- Biochemical Control in Acromegaly With Multimodality Therapies: Outcomes From a Pituitary Center and Changes Over Time.The Journal of clinical endocrinology and metabolism · 2020Article
- Gender differences and temporal trends over two decades in acromegaly: a single center study in 112 patients.Endocrine · 2020Article
- Review
- Pasireotide for the Medical Management of Feline Hypersomatotropism.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Certain clinical conditions and markers have recently been demonstrated to modify the natural history of acromegaly in affected patients. Thus, some clinical, histological, radiological and molecular factors are associated with more aggressive pituitary tumors that have higher biochemical activity, higher tumor volumes and decreased tumoral and biochemical responses to current therapies. However, these factors do not seem to have an equal influence on the prognosis of patients with acromegaly. We present a review of the factors that influence the clinical course of patients with acromegaly and propose a risk value for each factor that will allow prognostic scoring for affected patients by considering a combination of these factors.
Indexed as
Identifiers
24858722What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.